240 related articles for article (PubMed ID: 18667376)
1. Endocrine therapy of metastatic breast cancer.
Rodríguez Lajusticia L; Martín Jiménez M; López-Tarruella Cobo S
Clin Transl Oncol; 2008 Aug; 10(8):462-7. PubMed ID: 18667376
[TBL] [Abstract][Full Text] [Related]
2. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
5. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
6. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
7. Progression of endocrine therapies for breast cancer: where are we headed?
Arnedos M; Smith I
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
[TBL] [Abstract][Full Text] [Related]
8. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy in metastatic breast cancer.
Kimmick GG; Muss HB
Cancer Treat Res; 1998; 94():231-54. PubMed ID: 9587691
[TBL] [Abstract][Full Text] [Related]
10. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
Bauerschlag D; Schem C; Maass N; Jonat W
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S
Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
[TBL] [Abstract][Full Text] [Related]
12. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
[TBL] [Abstract][Full Text] [Related]
14. The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios C; Forbes JF; Jonat W; Conte P; Gradishar W; Buzdar A; Gelmon K; Gnant M; Bonneterre J; Toi M; Hudis C; Robertson JF
Ann Oncol; 2012 Jun; 23(6):1378-86. PubMed ID: 22317766
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
16. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
[TBL] [Abstract][Full Text] [Related]
17. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
18. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
19. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors: future directions.
Osborne CK; Schiff R
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]